Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations

EFPIA Newsletter 19 March 2020


#WeWontRest in the fight against COVID-19


Europe’s COVID-19 battle: supply, support and the search for diagnostics, vaccines, treatments...
18 March 2020

In any health emergency from HIV to SARS, Ebola to the coronavirus, attention turns to the research-based biopharmaceutical... Read more

Europe’s COVID-19 battle: working together to ensure the supply of medicines to the patients...
18 March 2020

EFPIA warmly welcomes this week’s adoption of a range of measures aimed at maintaining the free circulation of medicines... Read more

Tackling COVID-19: EFPIA welcomes proactive and regular dialogue with Commissioners on the...
13 March 2020

EFPIA joined a call with Health Commissioner Kyriakides, Commissioner Breton and Commissioner Lenarčič to discuss the... Read more


12 days left to apply for IMI Call21 to find solutions to tackle COVID-19




#WeWontRest in the fight against COVID 19
As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed... Read more

Diseases keep changing, and infections we treated for decades can once again kill. By bringing together researchers... Read more


What we are reading


Comparative tracker of EU and Global Covid-19 measures
On 19 March 2020 (Cicero/AMO)

Cicero developed a grid on measures taken to tackle the COVID-19 outbreak, detailing the response of the EU and its... Read more

Politico reporting on EFPIA's battle against Covid-19
On 19 March 2020 (Politico)

Europe’s branded pharma lobby EFPIA is underlining how much the EU needs the industry in situations like the current... Read more

Coronavirus: Commission offers financing to innovative vaccines company CureVac
On 16 March 2020 (European Commission)

The Commission offered up to €80 million of financial support to CureVac, a higly innovative vaccine developer from... Read more

COVID-19: developers of medicines or vaccines to benefit from free scientific advice
On 13 March 2020 (EMA)

EMA provides full fee waivers for scientific advice applications from developers of potential therapeutics (to treat... Read more

EFPIA calls pharma’s COVID-19 efforts ‘unprecedented’
On 12 March 2020 (The Pharma Letter)

Subscribers only. Read more